以细胞因子为靶点的抗哮喘药物研究进展

摘要/Abstract

摘要： 许多细胞因子在哮喘患者的气道慢性炎症与重构过程中起到关键作用,是抗哮喘药物的重要靶点。本文主要介绍了近年来以细胞因子(白细胞介素类、肿瘤坏死因子、嗜酸性粒细胞活化趋化因子)为靶点的抗哮喘药物最新进展和发展趋势,并就近年来涌现出的一些新的抗哮喘药物的研究进展作一综述。

关键词: 哮喘, 细胞因子, 药物治疗

Abstract: Several cytokines which play key role in asthma patients with chronic inflammation and reconstruction of air duct,are important targets for anti-asthma agents. In this review,we summarize the latest advancement of anti-asthma agents which targeted for cytokines(interleukins, TNF, eotaxin) and investigation development of new anti-asthma agents emerged in recent years.

Key words: Asthma, Cytokine, Drug therpy

中图分类号:

R562

蔡鑫君, 张相彩, 徐颖颖. 以细胞因子为靶点的抗哮喘药物研究进展[J]. 中国临床药理学与治疗学, 2010, 15(3): 350-355.

CAI Xin-jun, ZHANG Xiang-cai, XU Ying-ying. Progress on anti-asthma agents targeted for cytokine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 350-355.

参考文献

[1] Hopkin J. Mechanisms of asthma[J]. Medicine, 2003,31(12):41-44.
[2] Fang C, Corrigan CJ, Ying S.The treatment targets of asthma: from laboratory to clinic[J]. Allergy Drug Targets, 2008,7(2):119-128.
[3] Walsh GM. Advances in the immunobiology of eosinophils and their role in disease[J]. Crit Rev Clin Lab Sci, 1999,36(5):453-496.
[4] Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hypersonsiveness and the late asthmatic response[J]. Lancet, 2000,356(9248):2144-2148.
[5] Haldar P, Brightling CE, Hargadon B,et al.Mepolizumab and exacerbations of refractory eosinophilic asthma[J]. 2009,360(10):973-984.
[6] Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia[J]. N Engl J Med, 360(10):985-993.
[7] Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study[J]. Am J Respir Crit Care Med, 2003,167(12):1655-1659.
[8] Walsh GM.Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions[J]. Curr Opin Mol Ther, 2009,11(3):329-336.
[9] Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma[J]. Am J Respir Crit Care Med, 2008,178(10):1002-1008.
[10]Deshpande DA,Dogan S,Walseth TF, et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway[J]. Am J Respir Cell Mol Biol, 2004,31(1):36-42.
[11]Chiba Y,Nakazawa S, Todoroki M, et al. Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein[J]. Am J Respir Cell Mol Biol, 2009,40(2):159-167.
[12]Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial[J]. Am J Respir Crit Care Med, 1999,160(6):1816-1823.
[13]Ma Y, Hayglass KT, Becker AB, et al.Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice[J]. Allergy, 2007,62(6):675-682.
[14]Bree A, Schlerman FJ, Wadanoli M, et al. IL-13 blockade reduces lung infammation after Ascaris suum challenge in cynomolgus monkeys[J]. J Allergy Clin Immunol, 2007,119(5):1251-1257.
[15]Blanchard C, Mishra A, Saito-Akei H, et al. Inhibition of human interleukin-13-induced respiratory and oesophageal in?ammation by anti-human-interleukin-13 antibody (CAT-354)[J]. Clin Exp Allergy, 2005,35(8):1096-1103.
[16]Availableat:http://www.cambridgeantibody.com/data/assets/pdfle/11030/CAT-354Mar07.pdf. Accessed January, 11,2008.
[17]Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies[J]. Lancet, 2007,370 (9596):1422-1431.
[18]Shimbara A, Christodoulopoulos P, Soussi-Gounni A, et al. IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma[J]. J Allergy Clin Immunol, 2000,105(1Pt1):108-115.
[19]Cheng G, Arima M, Honda K, et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model[J]. Am J Respir Crit Care Med, 2002,166(3):409-416.
[20]White B, Leon F, White W, et al. Clinical therapeutics two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers[J]. Clin Ther, 2009,31(4):728-740.
[21]Hurst SD, Muchamuel T, Gorman DM, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25[J]. J Immunol, 2002,169(1):443-453.
[22]Kim MR, Manoukian R, Yeh R, et al.Transgenic overexpression of human IL-17E results in eosinophilia,B-lymphocyte hyperplasia,and altered antibody production[J]. Blood, 2002,100(7):2330-2340.
[23]Berry M, Brightling C, Pavord I, et al. TNF-alpha in asthma[J].Curr Opin Pharmacol, 2007,7(3):279-282.
[24]Morjaria JB, Chauhan AJ, Babu KS, et al.The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial[J]. Thorax, 2008,63(7):584-591.
[25]Erin EM,Leaker BR,Nicholson GC,et al.The effects of a monoclonal antibody directed against tumor necrosisfactor-alpha in asthma[J]. Am J Respir Crit Care Med, 2006,174(7):753-762.
[26]Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma[J]. J Allergy Clin Immunol, 2008,121(1):5-10.
[27]Rabinowitz MH, Andrews RC, Becherer JD, et al.Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)[J]. J Med Chem, 2001,44(24):4252-4267.
[28]Walsh GM. Targeting airway infammation: novel therapies for the treatment of asthma[J]. Current Medicinal Chemistry, 2006,13(25):3105-3111.
[29]Wegmann M, Gøggel R, Sel S, et al. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma[J]. Am J Respir Cell Mol Biol, 2007,36(1):61-67.
[30]Suzuki K, Morokata T, Morihira K, et al. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031[J]. Biochem Biophys Res Commun, 2006,339(4):1217-1223.
[31]Morokata T, Suzuki K, Masunaga Y, et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3[J]. J Pharmacol Exp Ther, 2006,317(1):244-250.
[32]Fryer AD, Stein LH, Nie Z, et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction[J]. J Clin Invest, 2006,116(1):228-236.
[33]Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy[J]. Drug News Perspect, 2008,21(8):434-439.
[34]Vollmer J, Krieg AM.Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists[J]. Adv Drug Deliv Rev, 2009,61(3):195-204.